Low-Dose Naltrexone Missed-Dose Protocol: What to Do and Why It Matters

The One-Sentence Missed-Dose Rule

Miss a dose? Skip it entirely and resume tomorrow night at your regular time. The pharmacokinetics of naltrexone at low doses make a same-day catch-up unnecessary and potentially counterproductive. Naltrexone's plasma half-life is approximately 4 hours, with its active metabolite 6-beta-naltrexol lasting 12 to 13 hours [1]. By the time most patients realize they forgot a nightly dose, the therapeutic window for that cycle has already closed.

Why Doubling Up Is a Bad Idea

Taking two capsules to "catch up" briefly saturates mu-opioid receptors for longer than intended. The LDN mechanism depends on a short, transient blockade followed by a rebound increase in endogenous opioid production [2]. Extending the blockade disrupts that rebound window, which is precisely the period when your body upregulates its own endorphin synthesis. One missed night is far less new to long-term outcomes than artificially prolonging receptor blockade.

What "Consistent Timing" Actually Means

Bedtime dosing between 9 PM and midnight is the standard clinical convention. This timing places peak receptor blockade during the 2 AM to 4 AM window when endogenous opioid production naturally peaks [3]. Missing one night shifts this cycle by 24 hours but does not permanently alter receptor expression. Two or more consecutive missed doses may begin to reduce the upregulation effect that accumulates over weeks of nightly treatment.

How Low-Dose Naltrexone Works

LDN's mechanism is distinct from full-dose naltrexone (50 mg) used in opioid-use disorder. At doses of 1.5 mg to 4.5 mg, the drug transiently blocks opioid receptors for 4 to 6 hours, then clears. The body responds by producing more endogenous opioids and by upregulating opioid receptor density [2]. That receptor upregulation, not the blockade itself, is thought to drive LDN's anti-inflammatory and analgesic effects.

The Endorphin Rebound Model

Bihari and colleagues originally proposed in the 1980s that brief opioid antagonism could paradoxically increase endorphin tone [4]. The hypothesis: when receptors are blocked, the brain interprets this as endorphin deficiency and compensates by producing more beta-endorphin and met-enkephalin. By morning, when naltrexone has cleared, those elevated endorphins bind to now-upregulated receptors, producing a sustained analgesic and immune-modulating effect that outlasts the drug itself.

Glial Cell Modulation

A second, increasingly well-supported pathway involves toll-like receptor 4 (TLR4) on microglial cells. Naltrexone at low concentrations acts as a TLR4 antagonist, reducing microglial activation and the release of pro-inflammatory cytokines including IL-6, TNF-alpha, and IL-1-beta [5]. This glial pathway may explain LDN's utility in central sensitization conditions like fibromyalgia and in neuroinflammatory diseases like multiple sclerosis.

Why Standard Naltrexone Doses Don't Work the Same Way

At 50 mg, naltrexone blocks receptors for 18 to 24 hours. The rebound endorphin effect is minimal because the blockade is too prolonged for strong compensatory upregulation [2]. Dose matters enormously here. The narrow therapeutic range of 1.5 mg to 4.5 mg is not arbitrary; it is the window that produces transient blockade without abolishing the rebound.

Clinical Evidence for LDN

LDN is used off-label. No FDA-approved indication exists at doses below 50 mg, and all supply comes through 503A compounding pharmacies [6]. The evidence base is growing but remains limited by small sample sizes and short follow-up periods. Here is what the primary literature actually shows.

Fibromyalgia: The Younger 2009 Crossover Trial

The most-cited LDN trial enrolled 10 women with fibromyalgia in a counterbalanced crossover design. Participants received 4.5 mg naltrexone nightly or placebo for 8 weeks each, separated by a 2-week washout. Mechanical and heat pain thresholds were measured weekly. LDN reduced fibromyalgia symptom scores by approximately 30% compared to placebo, a statistically significant difference (P<0.05) despite the small cohort [7]. The authors noted that LDN was well tolerated with vivid dreams as the predominant side effect in the first two weeks.

A follow-up crossover trial by Younger et al. In 2013 (N=31) replicated these findings at 4.5 mg nightly, reporting a mean 28.8% reduction in pain scores versus 18.0% with placebo [8].

Crohn's Disease: Pediatric and Adult Data

Smith et al. (2011) conducted a double-blind RCT in 40 adults with moderate-to-severe Crohn's disease. Patients received LDN 4.5 mg nightly for 12 weeks. Response rate was 88% in the LDN group versus 40% in placebo (P<0.001), and remission was achieved in 33% of LDN patients compared to 8% in placebo [9]. A pediatric pilot by the same group (N=14) showed 25% achieved remission on LDN 0.1 mg/kg nightly [10].

Multiple Sclerosis: Quality-of-Life Signals

Cree et al. (2010) ran a 16-week double-blind crossover trial in 80 patients with primary progressive MS. LDN 4.5 mg nightly did not significantly alter MRI lesion load, but patient-reported mental health quality of life improved significantly on the SF-36 mental health subscale compared to placebo [11]. This pattern, subjective benefit without objective lesion change, is consistent across several small MS trials and suggests LDN may be addressing neuroinflammatory symptoms rather than demyelination directly.

Dosing Schedules and Titration

Most prescribers start LDN at 1.5 mg nightly for 2 to 4 weeks, then increase to 3.0 mg, then to 4.5 mg if tolerated. Some patients remain at 1.5 mg or 3.0 mg if they achieve adequate symptom control or experience dose-limiting sleep disturbance.

The Standard Three-Step Titration

| Phase | Dose | Duration | |---|---|---| | Start | 1.5 mg nightly | 2 to 4 weeks | | Mid | 3.0 mg nightly | 2 to 4 weeks | | Maintenance | 4.5 mg nightly | Ongoing |

Patients with significant opioid sensitivity or low body weight may benefit from starting at 0.5 mg and titrating more slowly. Compounding pharmacies can prepare capsules in any of these strengths, as well as liquid formulations for precise micro-dosing [6].

Timing Flexibility Within the Night

Clinical practice varies. Some prescribers allow a 9 PM to 11 PM window; others use a fixed 10 PM target. The mechanistic rationale for nighttime dosing rests on aligning peak blockade with peak endogenous opioid release around 2 AM to 4 AM [3]. Patients who shift their bedtime by more than 2 hours regularly may want to discuss adjusting their LDN timing with their prescriber, not simply skipping doses.

What Happens If You Miss Doses Repeatedly

A single missed dose produces no clinically meaningful loss of effect. The receptor upregulation achieved over weeks of consistent dosing does not vanish overnight. Think of LDN's cumulative effect as a slowly filled reservoir: one missed night drains a small fraction, and the following night refills it.

Missing three or more consecutive doses may begin to attenuate the upregulation response, particularly in patients whose conditions are driven primarily by the endorphin rebound pathway rather than the TLR4 pathway [5]. Patients who have been on LDN for less than 8 weeks are more vulnerable to setbacks from missed doses because the receptor upregulation is still being established.

Re-Starting After a Gap

If you have missed more than 5 to 7 consecutive nights, discuss with your prescriber whether to restart at a lower dose (1.5 mg) for 1 to 2 weeks before returning to maintenance. This is not universally required, but it may reduce the risk of vivid dream recurrence, which is most common when LDN is introduced or re-introduced after a break.

Illness and Missed Doses

Patients on opioid-containing pain medications for acute illness (post-surgical opioids, opioid-based cough suppressants) must hold LDN entirely during that treatment course and for at least 7 to 10 days afterward [1]. Resuming LDN while opioids are still active in the system precipitates acute withdrawal. This is the one scenario where missing multiple doses is not only acceptable but medically necessary.

Side Effects and How Timing Affects Them

Sleep disturbance is the most frequently reported adverse effect, occurring in roughly 37% of patients in the first two weeks of the Younger 2009 trial [7]. Vivid, intense dreams tend to resolve spontaneously by weeks 3 to 4.

Managing Sleep-Related Side Effects

Moving the dose earlier in the evening (from 10 PM to 8 PM) can reduce the intensity of nocturnal dreams by shifting the blockade window slightly earlier. Some patients find the opposite works better for them, taking LDN closer to midnight so blockade peaks after most REM cycles have already occurred. Both strategies are worth trying before concluding LDN is not tolerable.

Nausea occurs in approximately 10% to 15% of patients during the first week and is almost always transient [8]. Taking LDN with a small amount of food reduces nausea without meaningfully altering absorption.

Rare but Serious Concerns

Hepatotoxicity is a labeling concern for full-dose naltrexone at 50 mg in the context of pre-existing liver disease [1]. At LDN doses of 1.5 mg to 4.5 mg, hepatotoxic risk is considered negligible, though no large-scale safety trials specifically in patients with hepatic impairment exist at these doses. Baseline liver function tests are reasonable before starting LDN in patients with known liver disease.

Drug Interactions with LDN

The most clinically significant interactions involve opioids, immunosuppressants, and thyroid medications.

Opioid Antagonism

Any opioid analgesic (oxycodone, hydrocodone, morphine, codeine, tramadol) will be blocked by LDN. Patients taking LDN for pain who require acute opioid analgesia should hold LDN 24 hours before the opioid is administered and for the full course afterward [1]. Emergency situations where this is not possible require the treating clinician to use higher-than-typical opioid doses, with careful monitoring, as receptor blockade reduces analgesic effect.

Thyroid Hormone Adjustment

Several clinicians managing patients on both LDN and thyroid replacement (levothyroxine) have reported that LDN's immune-modulating effects in autoimmune thyroid disease (Hashimoto's thyroiditis) may reduce thyroid antibody titers over time, potentially reducing the required thyroid hormone dose [12]. Thyroid function should be rechecked 8 to 12 weeks after starting LDN in patients on levothyroxine.

The HealthRX clinical team uses the following decision framework when patients on LDN report a missed dose:

1. Fewer than 12 hours since scheduled dose? Skip. Resume tomorrow night.
2. On acute opioids? Hold LDN for the full opioid course plus 7 days.
3. Missed 3 or more consecutive nights without opioid reason? Resume at current dose; consider dropping one titration step if sleep disturbance returns.
4. Missed 7 or more consecutive nights? Re-titrate starting at 1.5 mg for 2 weeks.
5. Unsure? Contact your prescriber before resuming; do not double-dose while waiting.

Compounding, Sourcing, and Legal Status

Standard pharmaceutical naltrexone is available as 50 mg tablets (brand name Vivitrol as an injectable, ReVia as oral) through conventional pharmacies. LDN at 1.5 mg to 4.5 mg does not exist as a commercially manufactured product [6]. All LDN is compounded off-label at 503A pharmacies under a valid physician prescription.

The FDA has not objected to this practice but has issued guidance that compounded drugs must not be copies of commercially available products in a way that circumvents the approval process [13]. Because 1.5 mg to 4.5 mg naltrexone capsules have no commercial equivalent, compounding is legally permissible under current FDA policy.

Quality varies by pharmacy. Patients and prescribers should verify that the compounding pharmacy holds current PCAB accreditation or equivalent state pharmacy board approval.

Who Should Not Take LDN

LDN is contraindicated in:

• Patients currently taking any opioid medication (absolute contraindication)
• Patients who have used opioids within the past 7 to 10 days [1]
• Patients with acute hepatitis or liver failure
• Pregnant patients (insufficient safety data at low doses)
• Patients with known hypersensitivity to naltrexone

Relative cautions apply to patients with a history of opioid use disorder who are in recovery. LDN does not cause physical dependence or euphoria, and its low-dose use does not compromise recovery. However, the prescribing clinician should coordinate with the patient's addiction medicine team before initiating LDN in this population.